Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

American Journal of Cardiology

Volumn 88, Issue 5, 2001, Pages 504-508

  Olsson, Anders G ^a   Pears, John ^b   McKellar, John ^b   Mizan, Jacques ^b   Raza, Ali ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ATORVASTATIN; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FLATULENCE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; REFERENCE VALUES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0035451307     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01727-1     Document Type: Article

References (16)

1. Pharmacological properties of ZD4522 - A new HMG-CoA reductase inhibitor
2. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells
3. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia
4. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
5. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT). I. Use of a dietary monitoring tool
6. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT). II. Food record rating as an indicator of compliance
7. Current perspectives on statins
8. Drug treatment of lipid disorders
9. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge
10. Statins: Effective antiatherosclerotic therapy
11. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
12. High apolipoprotein (apo) B and low apoA-1 improve the prediction of fatal myocardial infarction at all levels of cholesterol and triglycerides - Mortality data from the AMORIS (apolipoprotein-related mortality risk) study
13. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
14. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
15. Summary of the Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
16. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention